Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
|Articles|February 22, 2017
Explosion Pressure Relief Vent Improves Safety
Rembe’s Targo-Vent is an opening angle limiter for Rembe Explosion Panels that diverts flames and shock waves from a combustible dust explosion.
Combustible dust explosions occur within a few milliseconds and leave behind considerable damage. Different approaches can be implemented to limit this damage. Explosion panels are often used in facilities where release of the explosion to the surrounding external area is possible. Explosion panels, which relieve the explosions by bursting at a predetermined pressure point, are very economical and relatively easy to manage. This type of traditional explosion pressure relief, however, presents a problem because it requires extensive safety areas around the relief area to protect people, equipment, and the surrounding areas. These areas become unusable space.
Rembe Targo-Vent is an opening angle limiter developed especially for Rembe Explosion Panels that guides the pressure relief specifically into areas in which there is no danger to the adjoining infrastructure. Targo-Vent absorbs the forces of explosion energy and guides the flames and shock wave in the desired direction. Depending on the particular application or equipment, the flames and shock wave are diverted at a defined angle of approximately 30° to 45° upwards or to the side, so facility operators can minimize the safety areas around the vent opening. The top module is made in standard explosion-panel sizes for retrofitting to existing panels.
Source:
Related to this article
PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
FDA opens applications for its Expedited IND Pilot, pairing sponsors with qualified research institutions to test rolling CMC review ahead of first-in-human trials.
2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
Karthik Iyer, Eli Lilly, details an AI system linking GMP findings, audits, and deviations for cited, inspection-ready regulatory intelligence.
At the PDA/FDA Joint Regulatory Conference 2026, Helen Motamen, MS
global head, Sanofi Quality Audit, Inspection, Intelligence & Advocacy, at Sanofi, provided advice for creating a strong internal audit program.